ArticleScientific reports2025
Assessment of volatile component stability in Guanxin Jieyu granules through gas chromatography in accordance with Q14 guidelines.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Guanxin Jieyu Granules, a novel traditional Chinese medicine (TCM) in development, targets stable angina pectoris with accompanying anxiety. To improve stability, its volatile oil components—including borneol—are stabilized via β-cyclodextrin inclusion. In compliance with ICH Q14 guidelines, a gas chromatography (GC) analytical method was developed, incorporating knowledge management, risk management, experimental design, and results analysis, as well as performance evaluation of the analytical method. Accelerated Destructive Degradation Tests (ADDTs) using this method revealed a dramatic stability enhancement from β-cyclodextrin encapsulation. At 25 °C over 730 days, the inclusion complex showed only a 1.10% probability of failure (defined as ≥ 5% content loss), compared to 88.50% for the physical mixture. These results underscore the critical role of cyclodextrin inclusion in preserving volatile TCM constituents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.